Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRB | P24530 | 6/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 5/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | FEN1 | P39748 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14745574 | 0.98 | EDNRB (0.41) | EDNRBEGLN1TSHRMEN1KMT2A | |
| SCHEMBL14745744 | 0.93 | EGLN1 (0.39) | EDNRBEGLN1TSHRALDH1A1POLB | |
| SCHEMBL14745965 | 0.91 | EGLN1 (0.39) | EDNRBEGLN1TSHRMEN1KMT2A | |
| SCHEMBL16428825 | 0.85 | EDNRB (0.41) | EDNRBEGLN1TSHRMEN1KMT2A | |
| SCHEMBL14745374 | 0.85 | TSHR (0.39) | EDNRBEGLN1TSHRMEN1KMT2A | |
| SCHEMBL14745818 | 0.83 | KMT2A (0.39) | EDNRBEGLN1TSHRMEN1KMT2A | |
| SCHEMBL14746276 | 0.81 | EGLN1 (0.40) | EDNRBEGLN1TSHRMEN1KMT2A | |
| SCHEMBL14745792 | 0.81 | GABRG2 (0.44) | EGLN1TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL16429014 | 0.80 | EDNRB (0.39) | EDNRBEGLN1TSHRMEN1KMT2A | |
| SCHEMBL14745643 | 0.80 | TSHR (0.38) | EDNRBEGLN1TSHRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2750678-B1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | PTC THERAPEUTICS INC (US) | 2017-03-22 | — | — | EP | disclosed |
| US-20150038438-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | PTC THERAPEUTICS, INC. | 2015-02-05 | — | — | US | disclosed |
| EP-2750678-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | PTC Therapeutics, Inc. (US) | 2014-07-09 | — | — | EP | disclosed |
| WO-2013033228-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | PTC THERAPEUTICS, INC. (US) | 2013-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038438-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | MRPL21, SLC11A2, CLPP | EDNRB 3885/4885EGLN1 712/4885TSHR 4837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.